Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUV-868 in advanced solid tumors
NCT05252390Phase 1Terminated
- Sponsor
- Nuvation Bio
- Start
- Mar 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of nuv-868 in ovarian cancer, pancreatic cancer (PC), prostate cancer (PCa) and 1 more (7 arms), sponsored by Nuvation Bio. Primary endpoints: Dose-Limiting Toxicity at 28 days, Pharmacokinetics at 29 days and 5 more. Started Mar 2022; status: terminated.
02
Drugs
nuv-868
03
Conditions
ovarian cancerpancreatic cancer (PC)prostate cancer (PCa)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05252390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05252390.